1-hydroxymethylmidazolam has been researched along with efavirenz in 1 studies
Studies (1-hydroxymethylmidazolam) | Trials (1-hydroxymethylmidazolam) | Recent Studies (post-2010) (1-hydroxymethylmidazolam) | Studies (efavirenz) | Trials (efavirenz) | Recent Studies (post-2010) (efavirenz) |
---|---|---|---|---|---|
163 | 46 | 49 | 3,110 | 631 | 1,611 |
Protein | Taxonomy | 1-hydroxymethylmidazolam (IC50) | efavirenz (IC50) |
---|---|---|---|
Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain A, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
Chain B, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
Prothrombin | Bos taurus (cattle) | 0.022 | |
Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.1852 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.02 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 0.054 | |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.004 | |
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Human immunodeficiency virus 1 | 0.0035 | |
Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.1627 | |
Reverse transcriptase | Human immunodeficiency virus 1 | 0.0643 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kosugi, Y; Takahashi, J | 1 |
1 other study(ies) available for 1-hydroxymethylmidazolam and efavirenz
Article | Year |
---|---|
Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.
Topics: Administration, Oral; Alkynes; Animals; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Interactions; Haplorhini; Humans; Hydroxylation; Male; Microsomes, Liver; Midazolam; Nifedipine; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Species Specificity; Substrate Specificity; Testosterone | 2015 |